NVAX stock price: Novavax, Inc to complete 50% gain in a week after on coronavirus vaccine progress
Premium|Take advantage of 50% OFF on your first month.
Start your subscription and get access to all our original articles.
You have reached your limit of 5 free articles for this month.
Get Premium without limits for only $9.99 for the first month
Access all our articles, insights, and analysts.
UNLOCK OFFER- NASDAQ: NVAX is set to open Tuesday's trading some 6% higher, building on previous gains.
- Novavax Inc. announced it is kicking off a covid vaccine Phase 3 trial in the US and Mexico.
- Rival immunization schemes have faced issues, allowing Novavax a share of the pie.
Does the early bird get the worm? Not so fast. While three coronavirus vaccine efforts have already announced high levels of immunization, Novavax Inc (NASDAQ: NVAX) is still well-positioned to provide jabs to a world gripped with the disease.
The Gaithersburg, Maryland-based vaccine development firm announced that its Phase 3 trials in the US and Mexico are set to start in the next few weeks. Despite the delay – inoculations were originally planned to start in October in North America – production is ramping up
Novavax announced it is planning to produce vaccines at a commercial scale in the Fujifilm Diosynth Biotechnologies in North Carolina. The partnership with the Japanese-based company may result in mass output for Novavax's vaccines. Novavax has a significant advantage in the US – it is working closely with the federal government's Operation Warp Speed.
The firm's European operations are also moving forward. NVAX, which has facilities in Uppsala, Sweden, has completed enrollment for a 15,000-strong Phase 3 trial in the UK. It is also busy with a Phase 2b test in South Africa, which includes several HIV-positive participants. Trying the vaccine on a variety of populations could provide more robust data.
NVAX stock news
NASDAQ: NVAX is set to kick off trading at around $148, up over 6% on Tuesday. If these projected premarket figures become reality, stocks would complete an increase of roughly 50% in one week. Shares of the pharma firm traded under $100 last week and below $90 earlier in November.
Novavax, run by Stanley C. Erck, has made significant headway since trading at below $4 as its 52-week low. Excitement about a covid vaccine could push shares toward the 52-week high of $189.40.
- NASDAQ: NVAX is set to open Tuesday's trading some 6% higher, building on previous gains.
- Novavax Inc. announced it is kicking off a covid vaccine Phase 3 trial in the US and Mexico.
- Rival immunization schemes have faced issues, allowing Novavax a share of the pie.
Does the early bird get the worm? Not so fast. While three coronavirus vaccine efforts have already announced high levels of immunization, Novavax Inc (NASDAQ: NVAX) is still well-positioned to provide jabs to a world gripped with the disease.
The Gaithersburg, Maryland-based vaccine development firm announced that its Phase 3 trials in the US and Mexico are set to start in the next few weeks. Despite the delay – inoculations were originally planned to start in October in North America – production is ramping up
Novavax announced it is planning to produce vaccines at a commercial scale in the Fujifilm Diosynth Biotechnologies in North Carolina. The partnership with the Japanese-based company may result in mass output for Novavax's vaccines. Novavax has a significant advantage in the US – it is working closely with the federal government's Operation Warp Speed.
The firm's European operations are also moving forward. NVAX, which has facilities in Uppsala, Sweden, has completed enrollment for a 15,000-strong Phase 3 trial in the UK. It is also busy with a Phase 2b test in South Africa, which includes several HIV-positive participants. Trying the vaccine on a variety of populations could provide more robust data.
NVAX stock news
NASDAQ: NVAX is set to kick off trading at around $148, up over 6% on Tuesday. If these projected premarket figures become reality, stocks would complete an increase of roughly 50% in one week. Shares of the pharma firm traded under $100 last week and below $90 earlier in November.
Novavax, run by Stanley C. Erck, has made significant headway since trading at below $4 as its 52-week low. Excitement about a covid vaccine could push shares toward the 52-week high of $189.40.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.